AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%
Last update at 2024-04-18T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -87.40000M | -80.92600M | -57.45800M | -51.90300M | -86.73500M |
| Minority interest | - | - | - | - | - |
| Net income | -112.16900M | -91.79100M | -57.24000M | -59.72900M | -86.97500M |
| Selling general administrative | 37.72M | 77.42M | 59.04M | 74.67M | 79.72M |
| Selling and marketing expenses | 53.75M | - | - | - | - |
| Gross profit | 42.27M | 36.59M | 40.50M | 35.06M | 7.38M |
| Reconciled depreciation | 9.11M | 5.47M | 3.33M | 2.15M | 2.86M |
| Ebit | -68.92100M | -53.48300M | -24.78500M | -46.51000M | -80.99900M |
| Ebitda | -66.51000M | -53.61000M | -24.59500M | -46.43900M | -78.14200M |
| Depreciation and amortization | 2.41M | -0.12700M | 0.19M | 0.07M | 2.86M |
| Non operating income net other | -8.27900M | -18.70000M | -5.22900M | -1.00200M | -0.70100M |
| Operating income | -68.92100M | -53.48300M | -24.78500M | -46.51000M | -76.59500M |
| Other operating expenses | 168.69M | 128.93M | 89.93M | 109.55M | 108.92M |
| Interest expense | 24.77M | 16.58M | 9.47M | 10.91M | 9.44M |
| Tax provision | 0.00000M | 0.00000M | -0.21800M | 0.00000M | 0.24M |
| Interest income | 2.51M | 0.11M | 0.17M | 1.00M | 0.50M |
| Net interest income | -22.25600M | -16.46500M | -9.30400M | -9.90900M | -8.93800M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | 0.11M | 15.12M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 24.77M | 10.87M | -0.21800M | 7.83M | 0.24M |
| Total revenue | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M |
| Total operating expenses | 111.19M | 90.07M | 65.29M | 81.57M | 88.44M |
| Cost of revenue | 57.50M | 38.86M | 24.64M | 27.98M | 20.48M |
| Total other income expense net | -18.47900M | -27.44300M | -32.67300M | -5.39300M | 3.27M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -87.40000M | -80.92600M | -57.24000M | -51.90300M | -86.97500M |
| Net income applicable to common shares | -87.40000M | -80.92600M | -57.24000M | -51.90300M | -86.97500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 295.28M | 321.16M | 108.61M | 93.72M | 107.70M |
| Intangible assets | 1.15M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 25.48M | 3.48M | 3.28M | 3.21M | 2.56M |
| Total liab | 545.82M | 530.51M | 289.03M | 284.25M | 282.79M |
| Total stockholder equity | -250.53800M | -209.34900M | -180.41900M | -190.52600M | -175.08200M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 44.95M | 33.59M | 30.79M | 23.30M | 7.69M |
| Common stock | 2.64M | 2.52M | 2.42M | 2.12M | 1.87M |
| Capital stock | 2.64M | 2.52M | 2.42M | 2.12M | 1.87M |
| Retained earnings | -3217.46900M | -3130.06900M | -3049.14300M | -2991.90300M | -2940.00000M |
| Other liab | 105.18M | 106.39M | 95.95M | 102.25M | 116.36M |
| Good will | 2.43M | - | - | - | - |
| Other assets | 9.72M | 5.19M | 3.27M | 2.18M | 0.25M |
| Cash | 69.77M | 124.18M | 67.00M | 29.91M | 71.16M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 67.30M | 48.35M | 73.70M | 65.62M | 75.24M |
| Current deferred revenue | 1.73M | 0.83M | 33.27M | 32.50M | 50.87M |
| Net debt | 313.14M | 258.56M | 56.43M | 91.51M | 31.33M |
| Short term debt | 9.56M | 6.98M | 4.06M | 5.03M | 11.30M |
| Short long term debt | 9.56M | 6.98M | 4.06M | 5.03M | 11.30M |
| Short long term debt total | 382.91M | 382.74M | 123.44M | 121.41M | 102.49M |
| Other stockholder equity | 2964.29M | 2918.20M | 2866.30M | 2799.28M | 2763.07M |
| Property plant equipment | 45.13M | 36.61M | 25.87M | 26.78M | 25.60M |
| Total current assets | 234.90M | 219.74M | 79.48M | 60.76M | 81.85M |
| Long term investments | 1.96M | 56.62M | - | - | - |
| Net tangible assets | -254.11900M | -209.34900M | -180.41900M | -190.52600M | -175.08200M |
| Short term investments | 101.08M | 79.93M | 0.00000M | 19.98M | - |
| Net receivables | 16.80M | 4.99M | 4.22M | 3.51M | 4.02M |
| Long term debt | 368.00M | 223.94M | 5.00M | 5.00M | 91.19M |
| Inventory | 21.77M | 7.15M | 4.97M | 4.16M | 3.60M |
| Accounts payable | 11.05M | 6.96M | 5.58M | 4.79M | 5.38M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -0.01900M | -0.01900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 2.64M | 2.52M | 2.42M | 2.12M | 1.87M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -3217.46900M | -3130.06900M | -3049.14300M | -2991.90300M | -2940.00000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9.72M | 8.19M | 3.27M | 6.19M | 0.25M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 60.39M | 101.42M | 29.13M | 32.97M | 25.85M |
| Capital lease obligations | 5.34M | 1.04M | 1.20M | 2.51M | - |
| Long term debt total | 225.40M | 223.94M | 5.00M | 5.00M | 19.10M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 4.87M | -137.07100M | 20.00M | -20.27800M | -0.23400M |
| Change to liabilities | -1.57700M | 15.14M | 4.14M | 2.90M | 0.64M |
| Total cashflows from investing activities | 4.87M | -151.53700M | 15.22M | -22.84300M | -0.23400M |
| Net borrowings | -0.01800M | 177.68M | 14.87M | 63.70M | -6.61000M |
| Total cash from financing activities | 21.39M | 270.27M | 49.85M | 69.86M | 61.29M |
| Change to operating activities | -24.77000M | -4.63000M | -2.64400M | -4.99600M | -4.03600M |
| Net income | -87.40000M | -80.92600M | -57.24000M | -51.90300M | -86.97500M |
| Change in cash | -54.41700M | 57.02M | 36.94M | -41.46200M | 23.33M |
| Begin period cash flow | 124.18M | 67.16M | 30.22M | 71.68M | 48.35M |
| End period cash flow | 69.77M | 124.18M | 67.16M | 30.22M | 71.68M |
| Total cash from operating activities | -80.67900M | -61.70900M | -28.12800M | -88.48300M | -37.73100M |
| Issuance of capital stock | 19.79M | 1.99M | 23.66M | 3.20M | 70.52M |
| Depreciation | 9.11M | 5.47M | 3.33M | 2.15M | 2.86M |
| Other cashflows from investing activities | -20.34100M | -3.00000M | -3.98300M | -20.27800M | 0.12M |
| Dividends paid | - | - | - | -0.65600M | - |
| Change to inventory | -5.67000M | -4.08100M | -1.31400M | -0.55800M | -3.15200M |
| Change to account receivables | -11.80700M | -0.77600M | -0.70500M | 0.50M | -1.33900M |
| Sale purchase of stock | 19.41M | -1.12800M | 0.68M | 0.66M | 67.90M |
| Other cashflows from financing activities | 1.62M | 319.45M | 25.50M | 122.93M | -4.22500M |
| Change to netincome | 10.86M | 24.84M | 30.42M | 0.87M | 5.23M |
| Capital expenditures | 7.59M | 11.47M | 4.78M | 2.56M | 0.35M |
| Change receivables | -11.80700M | -0.77600M | -0.70500M | 0.50M | -1.33900M |
| Cash flows other operating | 8.80M | -20.12000M | -5.57500M | -41.27100M | 45.01M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -54.41700M | 57.02M | 36.94M | -41.46200M | 23.33M |
| Change in working capital | -24.05400M | -17.73000M | -9.78000M | -12.36000M | 36.68M |
| Stock based compensation | 13.45M | 12.20M | 6.51M | 6.20M | 6.86M |
| Other non cash items | 8.22M | 6.63M | 18.40M | -28.00300M | 5.71M |
| Free cash flow | -88.26800M | -73.17500M | -32.91200M | -91.04800M | -38.08500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MNKD MannKind Corp |
-0.02 0.49% | 4.08 | - | 22.22 | 5.09 | - | 5.87 | 461.68 |
| NVO Novo Nordisk A/S |
-1.78 1.43% | 122.75 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.344 1.08% | 122.81 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.38 0.10% | 393.48 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-1.042 1.18% | 86.92 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
30930 Russell Ranch Road, Westlake Village, CA, United States, 91362
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael E. Castagna Pharm.D. | CEO & Director | 1977 |
| Mr. Steven B. Binder | Chief Financial Officer | 1963 |
| Mr. Joseph Kocinsky M.B.A., M.S. | Chief Technology Officer | 1964 |
| Dr. David B. Thomson | Exec. VP, Gen. Counsel & Sec. | 1967 |
| Dr. Stuart A. Tross Ph.D. | Chief People & Workplace Officer | 1967 |
| Mr. Thomas Hofmann M.D., Ph.D. | Chief Scientific Officer | NA |
| Ms. Rosabel Realica Alinaya | VP of Investor Relations & Treasury | 1961 |
| Mr. John F. Bedard | Sr. VP of Worldwide Regulatory Affairs | 1950 |
| Mr. James Patrick McCauley Jr., J.D., M.B.A. | Chief Commercial Officer | 1966 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...